Enanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Enanta Pharmaceuticals Inc ENTA.OQ reported a quarterly adjusted loss of 85 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.07. The mean expectation of four analysts for the quarter was for a loss of $1.28 per share. Wall Street expected results to range from $-1.68 to $-1.02 per share.

• Revenue rose 1.9% to $18.31 million from a year ago; analysts expected $15.54 million.

• Enanta Pharmaceuticals Inc's reported EPS for the quarter was a loss of 85 cents​.

• The company reported a quarterly loss of $18.26 million.

• Enanta Pharmaceuticals Inc shares had fallen by 8.7% this quarter and gained 20.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.4% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 65.5% above its last closing price of $6.90

This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)